Table 1.
Patient Characteristics (Open-Label Baseline, Safety Population)
| Characteristic | LUR-LURa (N = 136) | RIS-LURb (N = 87) |
|---|---|---|
| Male, n (%) | 102 (75.0) | 58 (66.7) |
| Age, mean (SD), y | 43.9 (10.7) | 42.8 (10.8) |
| Race, n (%) | ||
| White | 50 (36.8) | 39 (44.8) |
| Black | 67 (49.3) | 40 (46.0) |
| Asian | 6 (4.4) | 1 (1.1) |
| Other | 13 (9.6) | 7 (8.0) |
| Ethnicity, Hispanic/Latino, n (%) | 36 (26.5) | 25 (28.7) |
| Duration of illness, mean (SD), y | 16.9 (10.7) | 17.6 (11.9) |
| ≥4 hospitalizations, n (%) | 30 (22.1) | 25 (28.8) |
| PANSS total score, mean (SD) | 55.4 (13.6) | 55.5 (11.2) |
| CGI-S score, mean (SD) | 2.8 (0.8) | 2.9 (0.8) |
| MADRS score, mean (SD) | 5.1 (5.6) | 4.3 (4.4) |
CGI-S Clinical Global Impression-Severity Scale, LUR lurasidone, MADRS Montgomery-Åsberg Depression Rating Scale, PANSS Positive and Negative Syndrome Scale, RIS risperidone, SD standard deviation
a Patients who received lurasidone in both double-blind and open-label studies
b Patients who received risperidone during the double-blind study and were switched to lurasidone in the open-label study